Sarepta Sees ELEVIDYS Demand Stabilizing as FSHD, DM1 Readouts Near

Sarepta Therapeutics outlined plans to stabilize demand for its ELEVIDYS gene therapy and advance RNA-based programs targeting FSHD and DM1 at the Morgan Stanley Global Healthcare Conference. The update signals continued pipeline development, but provides no financial guidance, clinical data, or quantified demand outlook.